Clinical trials: Advanced HBV-Related Hepatocellular Carcinoma
Hepatocellular Carcinoma
Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells
To evaluate the safety, tolerability and efficacy of autologous γδT cells in the treatment of advanced hepatitis B-related hepatocellular carcinoma.
- Trial name
- NCT04032392
- Testing
- autologous γδT cells
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Beijing 302 Hospital
Advanced HBV-Related Hepatocellular Carcinoma
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma
This early phase (Phase 1) study will evaluate BRII 5395, administered in combination with two approved anticancer agents, sintilimab and bevacizumab, in patients with advanced liver cancer caused by chronic hepatitis B virus…
- Trial name
- NCT07557251
- Testing
- BRII-5395, Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced HBV-Related Hepatocellular Carcinoma (HCC)
The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects
The enriched HBV-related advanced HCC patient population (composite biomarker score ≥ 2) and overall survival (OS) were compared between the two groups.
- Trial name
- NCT03236636
- Testing
- Icaritin, HUACHANSU PIAN
- Where
- 28 sites in China
- Volunteers
- 312 people
- Sponsor
- Beijing Shenogen Biomedical Co., Ltd
Hepatocellular Carcinoma
Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC
Adoptive cell therapy with TCR-T cells targeting HBV antigens represents an innovative opportunity for treatment of HBV-related HCC.
- Trial name
- NCT05339321
- Testing
- SCG101, PD1/PD-L1 checkpoint inhibitor
- Where
- 4 sites in China
- Volunteers
- 36 people
- Sponsor
- Peking Union Medical College Hospital
Hepatitis B Virus Infection
Inhibition of HBV Replication and Biological Reversal of Cirrhosis (F3-F4) and HCC by Flavonoids
SB Flavonoids for Advanced Liver Disease ManagementSB Flavonoids represents a multi-target therapeutic composition engineered for the comprehensive management of Hepatitis (Acute and Chronic), Advanced Cirrhosis (F3)-(F4), and…
- Trial name
- Flavonoids (NCT07084948)
- Testing
- Flavonoid, Tenofovir
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 134 people
- Sponsor
- Trieu, Nguyen Thi, M.D.
HBV-HCC, Unresectable Advanced HBV-related Liver Cancer
Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
This study is a prospective, real-world study intended to evaluate the efficacy and safety of pegylated interferon alpha-2b (PegIntron®) combined with targeted immunotherapy in patients with unresectable intermediate and advanced…
- Trial name
- NCT07769827
- Testing
- Combined Peg IFNα-2b treatment group
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Jinling Hospital, China
Hepatocellular Carcinoma, Liver Cancer, Adult
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
This is an open-label and multi-center Phase 2 study to evaluate the safety and efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus (HBV)-antigen-specific T cell receptor (TCR) (LioCyx-M) as…
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Cell Carcinoma
- Trial name
- NCT05195294
- Testing
- LioCyx-M, Lenvatinib
- Volunteers
- 55 people
- Sponsor
- Lion TCR Pte. Ltd.
Liver Cancer, Hepatocellular Carcinoma
Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of mRNA vaccine for HBV-positive Advanced Hepatocellular Carcinoma.
- Trial name
- NCT05738447
- Testing
- HBV mRNA vaccine
- Where
- China
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- West China Hospital